This is consistent with the in vivo tumor growth inhibition shown in Figures 6 and 7, in which RS17 or B6H12 treatment inhibited HepG2 growth by blocking the interactions between CD47 on HepG2 and SIRPα on mouse macrophages. This evidence concerns the gene CD47 and neoplasm.